One contract. Every CRO and CDMO.
Discovery to manufacturing.
BioBridgeX is the neutral, qualified vendor of record for outsourced drug development. It connects biotech and pharma sponsors with qualified CRO and CDMO vendors across discovery, preclinical, clinical, and CMC manufacturing, under a single contract, one PO, and one consolidated invoice across every vendor.
Free for buyers. Self-serve quotes, no demo wall.
Measured across emerging-biotech buyers consolidating multi-vendor studies onto a single BioBridgeX contract.
What do buyers say?
Series A and B teams and academic spinouts use BioBridgeX to source qualified vendors, compare quotes, and contract once, with one PO and one invoice across every vendor.
We went from 50 hours of sourcing and contracting per study to about 6. One MSA covered four vendors across tox and bioanalytical.
Consolidating four vendors onto one MSA and one invoice gave finance a single source of truth. Onboarding that took weeks now takes days.
The quotes are structured and comparable. I evaluated three viral vector CDMOs on scale and timeline in an afternoon.
One counterparty, one onboarding, one invoice. Procurement signed off in days instead of weeks of repeated diligence.
I compared DMPK and tox capabilities on the merits, not on whoever answered my email first. The matching is genuinely neutral.
For a spinout with no procurement team, having qualification already done meant we could move on the science immediately.
We went from 50 hours of sourcing and contracting per study to about 6. One MSA covered four vendors across tox and bioanalytical.
Consolidating four vendors onto one MSA and one invoice gave finance a single source of truth. Onboarding that took weeks now takes days.
The quotes are structured and comparable. I evaluated three viral vector CDMOs on scale and timeline in an afternoon.
One counterparty, one onboarding, one invoice. Procurement signed off in days instead of weeks of repeated diligence.
I compared DMPK and tox capabilities on the merits, not on whoever answered my email first. The matching is genuinely neutral.
For a spinout with no procurement team, having qualification already done meant we could move on the science immediately.
The science has moved on. The way you contract it hasn’t.
New modalities, leaner teams, more specialized vendors, yet sourcing a CRO or CDMO is still fragmented and demo-gated. Each provider is its own contract, PO, and invoice, with no neutral way to compare them. BioBridgeX replaces that with a single counterparty: one contract, one PO, one invoice across every vendor.
Fragmented sourcing
Cold outreach to dozens of CROs and CDMOs, then a separate contract, PO, and invoice for each one.
Demo-gated quotes
Every quote needs a sales call and an NDA. No transparent, comparable pricing you can actually decide on.
No neutral comparison
Incumbents sell their own capacity. Directories are lead-gen. Neither vets depth or compares quotes.
Contracting overhead
Legal, finance, and procurement repeat the same MSA, redlines, and onboarding for every vendor.
One contract, one PO, one invoice
BioBridgeX is the single counterparty across every CRO and CDMO you use.
Transparent, comparable quotes
Self-serve structured quotes, no demo wall. Decide on price, timeline, and capability side by side.
Neutral, published standard
No owned CROs, no pay-for-ranking. BioBridgeX Verify makes pre-qualified vendors verifiable.
Full-spectrum, one counterparty
Discovery to manufacturing, every indication and modality, under one wrapper.
From RFQ to signed SOW in 6 days
Four steps for buyers. Describe the study, get matched with qualified vendors, compare quotes, and sign one contract for every vendor.
Describe your study
Scope, modality, indication, timeline, and budget. About five minutes, self-serve.
Get matched with qualified vendors
BioBridgeX Verify surfaces qualified CROs and CDMOs with the right accreditation and scale.
Compare quotes side by side
Transparent, structured quotes. Compare price, timeline, and capability, then choose.
One contract, one invoice
Sign once with BioBridgeX. Get a single PO and one consolidated invoice across every vendor, on standard terms.
See every quote side by side
No demo wall, no back-and-forth email threads. Matched vendors return structured, comparable quotes. Score them on price, timeline, and capability, then sign one contract for every vendor.
- Structured quotes, normalized for apples-to-apples comparison
- BioBridgeX Verify score on every vendor
- Accept, negotiate, or award without leaving the platform
What can you outsource through BioBridgeX?
Every stage of drug development, from target ID to commercial supply. Browse qualified CRO and CDMO categories by development stage. Each links to its full service page with matched vendors.
Discovery
8 categoriesFind and optimize a candidate: targets, assays, chemistry, and AI-driven design.
- Target ID & Validation
- Assay Development & Screening
- Hit-to-Lead
- Lead Optimization
- Medicinal & Synthetic Chemistry
Preclinical
7 categoriesCharacterize pharmacology, DMPK, and early safety before IND.
- In Vitro Pharmacology
- In Vivo Pharmacology & Efficacy
- DMPK / ADME
- PK/PD & Modeling
- Bioanalytical
IND-Enabling
7 categoriesGLP toxicology and the regulatory package to file your IND.
- GLP Toxicology
- Safety Pharmacology
- Genetic Toxicology
- Reproductive / Developmental Tox (DART)
- Toxicokinetics
Clinical
9 categoriesPhase 1 to 4 operations, data, biostatistics, and pharmacovigilance.
- Clinical Operations
- Phase 1 Unit
- Clinical Data Management
- Biostatistics
- Medical Writing
CMC / Manufacturing
10 categoriesProcess and analytical development, drug substance, drug product, and fill-finish.
- Cell Line / Strain Development
- Process Development
- Analytical Development
- Viral Vector Manufacturing
- Plasmid DNA / mRNA / LNP
Commercial
5 categoriesCommercial manufacturing, supply chain, and lifecycle management.
- Commercial Manufacturing
- Supply Chain & Logistics
- Lifecycle Management
- CMC Regulatory
- Quality & Compliance (GxP)
Plus cross-stage Regulatory Affairs, CMC Regulatory, and Quality & Compliance (GxP).
All indications. All modalities. One platform.
Oncology is one therapeutic area among many. From small molecules to CAR-T, AAV gene therapy, ADCs, and mRNA, a buyer never outgrows the network.
Therapeutic areas
Modalities
What makes BioBridgeX different from a directory or an incumbent?
Directories are lead-gen with no qualification and no transaction layer. Incumbents sell their own capacity. BioBridgeX is neutral, qualified, transactional, and full-spectrum at the same time, which no other platform is.
Neutral by structure
No owned CROs, no pay-for-ranking. Rankings reflect fit and evidence, never who paid.
Published qualification standard
BioBridgeX Verify makes pre-qualified verifiable: accreditation, GxP status, and references.
One contract, PO, invoice
A single counterparty across every CRO and CDMO. Sign once, reconcile once.
Your vendor of record
One neutral counterparty contracts and pays every CRO and CDMO. Standard PO and invoice terms, reconciled once.
Self-serve transparent quotes
Structured, comparable quotes with no demo wall. Decide on price, timeline, and capability.
Free for buyers
Buyers pay no platform fee. A flat 2% on vendor quotes funds the network, disclosed up front.
How does qualification actually work?
BioBridgeX Verify is a published standard, not a badge we hand out. Every vendor is checked on accreditation, GxP compliance, capability evidence, and verified references before they can quote. The methodology is public.
Read the qualification methodologyAccreditation verified
Registrations and certifications confirmed at the source, not self-asserted.
GLP / GMP / GCP status
Compliance scope checked per service line, with inspection history where available.
Capability evidence
Equipment, scale, and modality experience evidenced, from bench to commercial.
Verified references
Sponsor references confirmed. Performance signals tracked across completed SOWs.
Who is BioBridgeX for?
Scientists, procurement, finance, and vendor BD each get what they need from the same platform, without trading off against each other.
Scientist
Find the right model and method fast. Compare DMPK, xenograft, and tox capabilities on the merits.
Procurement
One qualified counterparty, one MSA, one onboarding. Vendor diligence already done.
Finance / CFO
Consolidated billing across vendors, standard payment terms, and an audit-ready trail in one place.
Vendor BD
Inbound, qualified demand from sponsors who match your capabilities. Self-onboard in minutes.
Two ways to grow your CRO or CDMO
Join the qualified marketplace for inbound demand, or hand us your pipeline and we will build it for you.
List your services
Join the qualified network and get inbound, matched buyer demand aligned to your capabilities. Self-onboard in minutes. A flat 2% on accepted quotes, nothing up front.
- Inbound demand matched to your modality and scale
- BioBridgeX Verify profile that buyers trust
- Paid on standard terms, within 15 days of the cleared invoice
Outsourced BD: we build your pipeline
For CROs and CDMOs without BD capacity, BioBridgeX is your external business development arm: ICP prospecting, multi-channel outreach, and booked meetings with your ideal biotech and pharma buyers.
Questions buyers and vendors ask
BioBridgeX is a neutral, qualified vendor of record for outsourced drug development. It connects biotech and pharma buyers with qualified CRO and CDMO vendors across discovery, preclinical, clinical, and CMC manufacturing, under one contract, one PO, and one invoice.
Every vendor passes BioBridgeX Verify, a published standard: accreditation checks, GLP/GMP/GCP compliance scope, capability evidence, and verified sponsor references. Qualification is done before a vendor can quote, and the methodology is public.
Yes, buyers pay no platform fee. BioBridgeX charges a flat 2% on vendor quotes, disclosed up front. You get one PO and one consolidated invoice across every vendor, on standard net terms.
The buyer owns the study data and resulting IP, as set out in the SOW and Data & IP Ownership terms. BioBridgeX is the contracting and payment counterparty and does not perform the science or claim the results.
A CRO (contract research organization) runs research and development studies: discovery, pharmacology, tox, and clinical. A CDMO (contract development and manufacturing organization) develops and manufactures the drug substance and drug product. BioBridgeX covers both.
All of them. From oncology to rare disease, and from small molecules to peptides, antibodies, ADCs, oligonucleotides, mRNA, AAV gene therapy, and CAR-T cell therapy. A buyer never outgrows the network.
For CROs and CDMOs without BD capacity, BioBridgeX acts as an external business development team: ICP prospecting, multi-channel outreach, meeting setting, and pipeline reporting, with 25+ meetings booked per month and an 18% response rate.
Source your next study with one contract
Compare transparent quotes from qualified CRO and CDMO vendors, then contract once, with one PO and one invoice across every vendor. Free for buyers.